OX40L pipeline: Data Byte

Kymab leads the pack among companies targeting OX40L for autoimmune disorders, while Moderna has the most advanced program against the target for cancer. 

OX40L, the ligand for the OX40 receptor, is expressed on activated antigen-presenting cells, while the OX40 receptor is expressed on activated T cells. The interaction between OX40 and OX40L provides a co-stimulatory signal that regulates the proliferation and survival of T cells. ...